Cargando…
Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
Two new targeted agents have been approved for pediatric and adult patients with advanced or metastatic solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusion without an acquired resistance mutation. Larotrectinib and entrectinib are the second and third agents to be approved as...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863124/ https://www.ncbi.nlm.nih.gov/pubmed/33604102 http://dx.doi.org/10.6004/jadpro.2020.11.4.9 |